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 Th e risk of cardiovascular disease is high 
in patients with chronic kidney disease, 
and cardiovascular disease accounts for up 
to 50 % of deaths in this population. In the 
subset of patients receiving hemodialysis 
the rate of cardiovascular mortality is 10 – to 
20 – fold higher than that of the general 
population. 1 In addition to a high preva-
lence of traditional cardiovascular risk 
factors in patients with chronic renal 
disease (for example, hypertension and 
diabetes mellitus), other specific risk 
factors, including degree of uremia, 
comorbidity, inflammatory response, 
hypoalbuminemia, and hyperparathy-
roidism, also seem to contribute to the 
excess cardiovascular risk. 
 Th e antiphospholipid syndrome (APS) 
is an acquired, strongly prothrombotic 
disease characterized by arterial and ven-
ous thromboembolism and / or pregnancy 
morbidity in the presence of persistent 
high-titer autoantibodies directed against 
a broad range of phospholipids and phos-
pholipid-binding proteins. 2 Th e history of 
APS dates back to reports in the 1950  s 
of false-positive laboratory test results 
for syphilis in patients who went on 
to develop systemic lupus erythema tosus 
(SLE). It became apparent that Wasserman 
 et al. had detected the earliest anti-phos-
pholipid antibodies in 1906 with the 
development of a complement-fi xation 
assay for syphilis using phospholipid anti-
gen from hepatic extract of fetuses with 
congenital syphilis. 3 Th is phospho lipid 
antigen was later named  ‘ cardiolipin ’ (as 
subsequently mitochondrial phospholip-
ids were extracted from bovine heart mus-
cle), and anti-cardiolipin antibody 
detection became the basis of the current-
day Venereal Disease Research Laboratory 
(VDRL) test for syphilis. Widespread 
screening of donated blood for syphilis led 
to the realization that some patients with 
SLE possessed anti-phospholipid antibod-
ies resulting in false-positive VDRL tests, 
prolonged laboratory clotting times, and 
strong predisposition to thrombosis. 
 Anti-phospholipid antibodies are 
detected either by a prolongation of phos-
pholipid-dependent coagulation tests 
(lupus anticoagulant) or by solid-phase 
immune assays. Th ey are a heterogeneous 
group of autoantibodies directed against 
a variety of diff erent antigens (including 
prothrombin, annexin V, protein C, and 
protein S); it is thought that binding of 
these antigens is at least partly responsible 
for the prothrombotic phenotype of APS. 
In the early 1990s, several groups reported 
that a proportion of anti-cardiolipin anti-
bodies were directed against the phos-
pholipid cofactor   2 glycoprotein I 
(  2GPI). Th is single-chain polypeptide 
glycoprotein is a 50 – kDa plasma apolipo-
protein (plasma concentration 200   g / ml) 
that binds anionic phospholipids; it is 
required for anti-phospholipid antibody 
binding in a subset of patients with SLE 
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and APS. 4   2GPI is an abundant circulat-
ing protein synthesized by hepatocytes; 
although its precise physiological role 
remains unclear,   2GPI seems to have a 
function both in modulating platelet acti-
vation and in innate immune defenses, 
including removal of cellular waste and 
microparticles. The immune function 
seems to be related to the structural con-
formation of the protein, which exists in 
at least two diff erent forms ( ‘ circular ’ and 
active  ‘ open ’ forms). It is thought that 
  2GPI antibody formation might be 
related to the conformation change in the 
antigen seen in the presence of infection. 5 
  2GPI in the circulation exists in the  ‘ cir-
cular ’ conformation where the epitopes 
for autoantibodies are hidden; exposure 
of these cryptic epitopes is then necessary 
for formation of anti-  2GPI antibodies. 
  2GPI is now recognized as the major 
antigen for anti-phospholipid antibodies 
in APS; autoantibodies against   2GPI 
(particularly IgG against the N-terminal 
part of  β 2, domain I) are strongly associ-
ated with both thrombosis and the other 
clinical features of the syndrome. 
  2GPI has been identifi ed in atheroma-
tous plaques, and it is thought that anti-
bodies directed against   2GPI may have 
a role in accelerated atherosclerosis. 5 
Circulating oxidized low-density lipopro-
tein –  2GPI complexes have been detected 
in patients with SLE and in APS, which 
suggests a role for these in autoimmune-
related atherosclerosis; however, it is 
unclear whether this accelerated athero-
sclerosis is a consequence of underlying 
autoimmune disease rather than specifi -
cally due to   2GPI antibody in these 
patients. Anti-phospholipid antibody has 
also been associated with accelerated 
atherosclerosis in murine models, in 
which infused antibody or induction of 
antibody against murine   2GPI led to 
increased atherosclerotic plaque forma-
tion. 5   2GPI antibodies have been shown 
to cause endothelial dysfunction  in vitro , 
producing an inflammatory and pro-
thrombotic phenotype including cross-
reactivity with oxidized low-density 
lipoproteins. 
 Th e diagnosis of APS is based on strict 
clinical and laboratory criteria. Consensus 
guidance for APS diagnosis (the  ‘ Sapporo 
criteria ’ ) 6 was published in 1999; the 
revised 2006  ‘ Sydney criteria ’ saw the 
inclusion of antibodies against   2GPI as 
part of the diagnostic algorithm ( Table 1 ). 7 
Although APS may aff ect any organ, the 
current clinical diagnostic criteria are 
restricted to pregnancy loss and / or throm-
boembolism. Venous thrombosis (deep 
vein thrombosis and pulmonary embo-
lism) is the most frequent clinical manifes-
tation of APS, occurring in up to 55 % of 
patients; arterial thromboembolism is less 
common and manifests mostly as stroke 
and coronary ischemia. Notably, the cur-
rent diagnostic laboratory criteria include 
only IgG and IgM antibody positivity to 
cardiolipin and / or   2GPI, although the 
IgM isotype is less frequently associated 
with clinical features of APS. IgA anti-
phospholipid antibody does not appear 
in either of the diagnostic classifi cations; 
the authors of the Sydney criteria did not 
consider there to be suffi  cient evidence 
at the time to include isolated IgA anti-
  2GPI positivity in the laboratory diagno-
sis of APS. 
 Th e case for the clinical relevance of IgA 
anti-  2GPI is supported by the single-
center study by Serrano and co-workers 8 
(this issue), which reports the prevalence 
of anti-cardiolipin and anti-  2GPI anti-
bodies in a group of 124 patients on hemo-
dialysis for end-stage renal disease. 
Interes tingly, almost one-third of these 
patients were positive for IgA anti-  2GPI, 
and these subjects had signifi cantly higher 
overall mortality, cardiovascular mortality, 
and thrombotic event rate. An increased 
prevalence of both arteriovenous fi stula 
(AVF) and non-AVF thrombosis was seen 
in this group. It is noteworthy that the 
majority of subjects possessing IgA anti-
  2GPI did not have a diagnosis of underly-
ing autoimmune disease (with just above 
one-third reported as having a diagnosis of 
diabetic nephropathy) and were not of an 
African-American background (in which 
an increased incidence of IgA anti-  2GPI 
is well recognized). Data on lupus anti-
coagulants are not presented, which is 
surprising given their particularly strong 
association with thromboembolism in 
APS. Th e reason for generation of IgA anti-
  2GPI in dialysis patients is unclear, but 
the authors speculate that binding of circu-
lating   2GPI to dialysis membranes might 
reveal a neoepitope for antibody binding, 
resulting in a prothrombotic phenotype; it 
would be of interest to identify the   2GPI 
domain to which antibodies were directed 
in these subjects. Th e investigators suggest 
that testing dialysis patients for IgA anti-
  2GPI antibodies might identify a sub-
group of dialysis patients at increased risk 
of adverse cardiovascular events who 
might benefi t from additional therapeutic 
intervention and also from revision of the 
laboratory diagnostic criteria for APS. 
However, given the relatively small number 
of patients in this study (and the varied 
types of vascular pathology reported), 
these findings require confirmation in 
larger multicenter studies. 
 Table 1  |  Laboratory tests for APS: comparison of Sapporo 6 and Sydney 7 criteria 
  Sapporo (1999)  Sydney (2006) 
 Lupus anticoagulant  Positive on two or more 
occasions at least 6 weeks 
apart 
 Positive on two or more occasions 
at least 12 weeks apart 
 Anti-cardiolipin 
antibodies 
 Detection by standardized 
  2GPI ELISA 
 Detection by standardized ELISA 
  IgG and / or IgM of medium 
or high titer 
 IgG and / or IgM of medium or high 
titer (>40 units IgG or IgM titer or 
>99th percentile) 
  Positive on two or more 
occasions at least 6 weeks 
apart 
 Positive on two or more occasions at 
least 12 weeks apart 
 Anti-  2GPI antibodies  Not included  IgG and / or IgM titer >99th percentile 
Positive on two or more occasions 
at least 12 weeks apart 
 Abbreviations:  β 2GPI,  β 2 glycoprotein I; APS, antiphospholipid syndrome; ELISA, enzyme-linked immunosorbent 
assay. 
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 In most cases of APS, IgA anti-phos-
pholipid antibodies are found in the pres-
ence of other isotypes. 7 Th ere are, however, 
a limited number of reports in the litera-
ture of patients (with and without lupus) 
with clinical features of APS (including 
recurrent pregnancy loss, stroke, and myo-
cardial infarction) and isolated IgA anti-
  2GPI positivity. 9,10 IgA anti-cardiolipin 
antibody has been associated with ischemia 
in patients with coronary artery disease 
and has also been reported to be predictive 
of onset and outcome of acute coronary 
syndrome including unstable angina and 
ST-elevation myocardial infarction. 
Although IgA anti-  2GPI antibodies are 
not currently part of the diagnostic criteria 
for APS, they are reported to appear more 
frequently in certain groups, including 
African-American patients with SLE and 
obstetric patients with lupus and APS. 
Th us there is growing evidence that IgA 
anti-  2GPI testing might identify a small 
subset of patients with APS falling outside 
the Sydney criteria for APS, and that it may 
therefore be appropriate to test for IgA 
anti-  2GPI in patients with clinical 
features of APS who are negative for the 
currently recommended laboratory tests. 
Th e report of a high prevalence of isolated 
IgA anti-  2GPI in renal dialysis is intrigu-
ing; although this fi nding requires valida-
tion in larger future studies, it strengthens 
the case for an improved laboratory and 
clinical classifi cation of APS. Th ere are, 
aft er all, more than 25 diff erent autoanti-
bodies described in APS directed against 
phospholipids and / or phospholipid-bind-
ing proteins with diff ering pathogenicities. 
Multiple potential pathogenic mechanisms 
for thrombosis may be present in APS; 
a frequent characteristic in APS patients is 
platelet activation, which may have a key 
role in thrombosis in addition to other 
potential mechanisms, including inhibi-
tion of anticoagulation, reduced fi brino-
lysis, and direct eff ects on endothelium. 
No doubt the diagnostic clinical and 
laboratory criteria for this heterogeneous 
disease will continue to evolve; for now it 
is too early to recommend routine testing 
for IgA anti-  2GPI in renal patients on the 
basis of a single study. 
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